Drug intelligence / Profile preview

IB-002A

Development stage: Unknown
Lead developer: ILiAD Biotechnologies
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

IB-002A is a therapeutic vaccine developed by ILiAD Biotechnologies. It is derived from the B-Tech platform and is being investigated as an immunostimulant, specifically designed to optimize therapeutic effects for allergic diseases such as asthma. The drug acts by stimulating the immune system, aiming to prevent or treat immune-mediated respiratory conditions. Preclinical studies with related B-Tech candidates have shown protection against allergic airway inflammation and contact dermatitis in animal models, and ongoing research includes potential applications in neurodegenerative disease models. As of March 2025, IB-002A has reached early Phase 1 clinical development for asthma[1][7].

Beyond the preview

Go deeper on IB-002A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IB-002A.

Explore the full profile